BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes AM. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther. 2014;39:984-991. [PMID: 24617286 DOI: 10.1111/apt.12693] [Cited by in Crossref: 71] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Choi HG, Lee HK, Kang HS, Lim H, Kim J, Kim JH, Kim NY, Cho S, Nam ES, Min K, Kwon MJ. Possible Association between the Use of Proton Pump Inhibitors and H2 Receptor Antagonists, and Esophageal Cancer: A Nested Case–Control Study Using a Korean National Health Screening Cohort. Pharmaceuticals 2022;15:517. [DOI: 10.3390/ph15050517] [Reference Citation Analysis]
2 Tan WK, di Pietro M. Barrett’s Oesophagus: Today’s Mistake and Tomorrow’s Wisdom in Screening and Prevention. Visc Med. [DOI: 10.1159/000522015] [Reference Citation Analysis]
3 Laquière A, Trottier-tellier F, Urena-campos R, Lienne P, Lecomte L, Katsogiannou M, Penaranda G, Boustière C, Nakamura M. Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study. Gastroenterology Research and Practice 2022;2022:1-6. [DOI: 10.1155/2022/1606944] [Reference Citation Analysis]
4 Yao H, Wang L, Li H, Xu S, Bai Z, Wu Y, Chen H, Goyal H, Qi X. Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 2021;:1-10. [PMID: 34806503 DOI: 10.1080/17512433.2022.2008909] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Teufel A, Quante M, Kandulski A, Hirth M, Zhan T, Eckardt M, Thieme R, Kusnik A, Yesmembetov K, Wiest I, Riemann JF, Schlitt HJ, Gockel I, Malfertheiner P, Ebert MP. [Prevention of gastrointestinal cancer]. Z Gastroenterol 2021;59:964-82. [PMID: 34507375 DOI: 10.1055/a-1540-7539] [Reference Citation Analysis]
6 Alkhayyat M, Kumar P, Sanaka KO, Thota PN. Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma. Therap Adv Gastroenterol 2021;14:17562848211033730. [PMID: 34434254 DOI: 10.1177/17562848211033730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhang L, Sun B, Zhou X, Wei Q, Liang S, Luo G, Li T, Lü M. Barrett's Esophagus and Intestinal Metaplasia. Front Oncol 2021;11:630837. [PMID: 34221959 DOI: 10.3389/fonc.2021.630837] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Fedorova E, Watson TJ. Antireflux and Endoscopic Therapies for Barrett Esophagus and Superficial Esophageal Neoplasia. Surg Clin North Am 2021;101:391-403. [PMID: 34048760 DOI: 10.1016/j.suc.2021.03.002] [Reference Citation Analysis]
9 Kew GS, Soh AYS, Lee YY, Gotoda T, Li YQ, Zhang Y, Chan YH, Siah KTH, Tong D, Law SYK, Ruszkiewicz A, Tseng PH, Lee YC, Chang CY, Quach DT, Kusano C, Bhatia S, Wu JCY, Singh R, Sharma P, Ho KY. Multinational survey on the preferred approach to management of Barrett’s esophagus in the Asia-Pacific region. World J Gastrointest Oncol 2021; 13(4): 279-294 [PMID: 33889279 DOI: 10.4251/wjgo.v13.i4.279] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Chen Y, Sun C, Wu Y, Chen X, Kailas S, Karadsheh Z, Li G, Guo Z, Yang H, Hu L, Zhou Q. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis. J Cancer Res Clin Oncol 2021;147:2681-91. [PMID: 33575855 DOI: 10.1007/s00432-021-03544-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Snider EJ, Kaz AM, Inadomi JM, Grady WM. Chemoprevention of esophageal adenocarcinoma. Gastroenterol Rep (Oxf) 2020;8:253-60. [PMID: 32843972 DOI: 10.1093/gastro/goaa040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Scarpignato C, Sloan JA, Wang DH, Hunt RH. Gastrointestinal pharmacology: practical tips for the esophagologist. Ann N Y Acad Sci 2020;1481:90-107. [PMID: 32822080 DOI: 10.1111/nyas.14447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Yin CY, Zhang SS, Zhong JT, Zhou SH. Pepsin and Laryngeal and Hypopharyngeal Carcinomas. Clin Exp Otorhinolaryngol 2021;14:159-68. [PMID: 32734742 DOI: 10.21053/ceo.2020.00465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
14 Rosemurgy A, Wilfong C, Craigg D, Co F, Sucandy I, Ross S. The Evolving Landscape of Esophageal Cancer: A Four-Decade Analysis. The American Surgeon 2019;85:944-8. [DOI: 10.1177/000313481908500933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Valenzano MC, Rybakovsky E, Chen V, Leroy K, Lander J, Richardson E, Yalamanchili S, McShane S, Mathew A, Mayilvaganan B, Connor L, Urbas R, Huntington W, Corcoran A, Trembeth S, McDonnell E, Wong P, Newman G, Mercogliano G, Zitin M, Etemad B, Thornton J, Daum G, Raines J, Kossenkov A, Fong LY, Mullin JM. Zinc Gluconate Induces Potentially Cancer Chemopreventive Activity in Barrett's Esophagus: A Phase 1 Pilot Study. Dig Dis Sci 2021;66:1195-211. [PMID: 32415564 DOI: 10.1007/s10620-020-06319-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Klimara MJ, Randall DR, Allen J, Figueredo E, Johnston N. Proximal reflux: biochemical mediators, markers, therapeutic targets, and clinical correlations. Ann N Y Acad Sci 2020;1481:127-38. [PMID: 32401362 DOI: 10.1111/nyas.14366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
17 McCormick CA, Samuels TL, Battle MA, Frolkis T, Blumin JH, Bock JM, Wells C, Yan K, Altman KW, Johnston N. H+/K+ATPase Expression in the Larynx of Laryngopharyngeal Reflux and Laryngeal Cancer Patients. Laryngoscope 2021;131:130-5. [PMID: 32250454 DOI: 10.1002/lary.28643] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
18 Samuels TL, Zimmermann MT, Zeighami A, Demos W, Southwood JE, Blumin JH, Bock JM, Johnston N. RNA Sequencing Reveals Cancer-Associated Changes in Laryngeal Cells Exposed to Non-Acid Pepsin. Laryngoscope 2021;131:121-9. [PMID: 32202667 DOI: 10.1002/lary.28636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
19 Broide E, Eindor-Abarbanel A, Shirin H, Richter V, Matalon S, Leshno M. Is administration of proton pump inhibitors in functional dyspepsia worth the risk of developing gastric cancer: a Markov model to bridge the gap between scientific evidence and clinical practice. BMJ Open 2020;10:e031091. [PMID: 32051298 DOI: 10.1136/bmjopen-2019-031091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Lee L, Ramos-Alvarez I, Ito T, Jensen RT. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome. Int J Mol Sci 2019;20:E5128. [PMID: 31623145 DOI: 10.3390/ijms20205128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
21 Samuels TL, Altman KW, Gould JC, Kindel T, Bosler M, Mackinnon A, Hagen CE, Johnston N. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma. The Laryngoscope 2019;129:2687-95. [DOI: 10.1002/lary.28051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
22 Chwiesko A, Kowal-Bielecka O, Sierakowski S. Perspectives on the interlinked nature of systemic sclerosis and reflux disease. Expert Rev Gastroenterol Hepatol. 2019;13:213-227. [PMID: 30791766 DOI: 10.1080/17474124.2019.1561274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
23 Triadafilopoulos G, Singh G. Editorial: less acid, less cancer? Is this the question? Aliment Pharmacol Ther 2018;48:877-8. [PMID: 30281839 DOI: 10.1111/apt.14958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Triadafilopoulos G, Friedland S. Precision care for Barrett's esophagus. Transl Gastroenterol Hepatol 2018;3:67. [PMID: 30363757 DOI: 10.21037/tgh.2018.09.10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
25 Hvid-Jensen F, Drewes AM. Should aspirin and PPIs be recommended for patients with Barrett's oesophagus? Lancet 2018;392:362-4. [PMID: 30057101 DOI: 10.1016/S0140-6736(18)31618-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Tan MC, El-serag HB, Yu X, Thrift AP. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther 2018;48:469-77. [DOI: 10.1111/apt.14895] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
27 Cunha N, Machado AP. Proton pump inhibitors and the risk of severe adverse events - A cardiovascular bombshell? Rev Port Cardiol (Engl Ed) 2018;37:859-63. [PMID: 29804887 DOI: 10.1016/j.repc.2017.10.012] [Reference Citation Analysis]
28 Lee Y, Urbanska AM, Hayakawa Y, Wang H, Au AS, Luna AM, Chang W, Jin G, Bhagat G, Abrams JA, Friedman RA, Varro A, Wang KK, Boyce M, Rustgi AK, Sepulveda AR, Quante M, Wang TC. Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus. Oncotarget 2017;8:203-14. [PMID: 27448962 DOI: 10.18632/oncotarget.10667] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
29 Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018;53:172-177. [PMID: 29477057 DOI: 10.1016/j.canep.2018.02.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
30 Curtius K, Wright NA, Graham TA. An evolutionary perspective on field cancerization. Nat Rev Cancer 2018;18:19-32. [PMID: 29217838 DOI: 10.1038/nrc.2017.102] [Cited by in Crossref: 157] [Cited by in F6Publishing: 194] [Article Influence: 31.4] [Reference Citation Analysis]
31 Riegler M, Kristo I, Asari R, Rieder E, Schoppmann SF. Dietary sugar and Barrett's esophagus. Eur Surg 2017;49:279-81. [PMID: 29250105 DOI: 10.1007/s10353-017-0494-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Quante M, Graham TA, Jansen M. Insights Into the Pathophysiology of Esophageal Adenocarcinoma. Gastroenterology. 2018;154:406-420. [PMID: 29037468 DOI: 10.1053/j.gastro.2017.09.046] [Cited by in Crossref: 31] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
33 Prichard DO, Byrne AM, Murphy JO, Reynolds JV, O'Sullivan J, Feighery R, Doyle B, Eldin OS, Finn SP, Maguire A, Duff D, Kelleher DP, Long A. Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin-αv trafficking. J Cell Mol Med 2017;21:3612-25. [PMID: 28941013 DOI: 10.1111/jcmm.13271] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
34 Hayakawa Y, Sethi N, Sepulveda AR, Bass AJ, Wang TC. Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? Nat Rev Cancer. 2016;16:305-318. [PMID: 27112208 DOI: 10.1038/nrc.2016.24] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 13.6] [Reference Citation Analysis]
35 Tan WK, di Pietro M, Fitzgerald RC. Past, present and future of Barrett's oesophagus. Eur J Surg Oncol 2017;43:1148-60. [PMID: 28256346 DOI: 10.1016/j.ejso.2017.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
36 Hu Q, Sun TT, Hong J, Fang JY, Xiong H, Meltzer SJ. Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis. PLoS One 2017;12:e0169691. [PMID: 28072858 DOI: 10.1371/journal.pone.0169691] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
37 Hayakawa Y, Chang W, Jin G, Wang TC. Gastrin and upper GI cancers. Current Opinion in Pharmacology 2016;31:31-7. [DOI: 10.1016/j.coph.2016.08.013] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
38 Fock KM, Talley N, Goh KL, Sugano K, Katelaris P, Holtmann G, Pandolfino JE, Sharma P, Ang TL, Hongo M, Wu J, Chen M, Choi MG, Law NM, Sheu BS, Zhang J, Ho KY, Sollano J, Rani AA, Kositchaiwat C, Bhatia S. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. Gut 2016;65:1402-15. [PMID: 27261337 DOI: 10.1136/gutjnl-2016-311715] [Cited by in Crossref: 91] [Cited by in F6Publishing: 85] [Article Influence: 15.2] [Reference Citation Analysis]
39 Zeb MH, Baruah A, Kossak SK, Buttar NS. Chemoprevention in Barrett's Esophagus: Current Status. Gastroenterol Clin North Am 2015;44:391-413. [PMID: 26021201 DOI: 10.1016/j.gtc.2015.02.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
40 Greene CL, Worrell SG, Demeester TR. Rat Reflux Model of Esophageal Cancer and Its Implication in Human Disease. Annals of Surgery 2015;262:910-24. [DOI: 10.1097/sla.0000000000001207] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
41 Domper Arnal MJ, Ferrández Arenas &, Lanas Arbeloa &. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol 2015; 21(26): 7933-7943 [PMID: 26185366 DOI: 10.3748/wjg.v21.i26.7933] [Cited by in CrossRef: 461] [Cited by in F6Publishing: 435] [Article Influence: 65.9] [Reference Citation Analysis]
42 Samuels T, Hoekzema C, Gould J, Goldblatt M, Frelich M, Bosler M, Lee SH, Johnston N. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma. Ann Otol Rhinol Laryngol. 2015;124:893-902. [PMID: 26077392 DOI: 10.1177/0003489415590657] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
43 Dunbar KB, Souza RF, Spechler SJ. The Effect of Proton Pump Inhibitors on Barrett’s Esophagus. Gastroenterology Clinics of North America 2015;44:415-24. [DOI: 10.1016/j.gtc.2015.02.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
44 Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, Hur C, Luebeck EG. The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2015;24:1012-23. [PMID: 25931440 DOI: 10.1158/1055-9965.EPI-15-0323-T] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
45 Yanova OB, Berezina OI, Vasnev OS, Bordin DS. [Complicated gastroesophageal reflux disease in the presence of congenital esophageal shortening]. Ter Arkh 2015;87:77-9. [PMID: 25864354 DOI: 10.17116/terarkh201587277-79] [Reference Citation Analysis]
46 Whitson MJ, Falk GW. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus. Gastroenterol Clin North Am 2015;44:299-315. [PMID: 26021196 DOI: 10.1016/j.gtc.2015.02.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
47 Zayachkivska O, Bula N, Khyrivska D, Gavrilyuk E, Wallace JL. Exposure to non-steroid anti-inflammatory drugs (NSAIDs) and suppressing hydrogen sulfide synthesis leads to altered structure and impaired function of the oesophagus and oesophagogastric junction. Inflammopharmacology. 2015;23:91-99. [PMID: 25711289 DOI: 10.1007/s10787-015-0230-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
48 Kapoor H, Agrawal DK, Mittal SK. Barrett's esophagus: recent insights into pathogenesis and cellular ontogeny. Transl Res 2015;166:28-40. [PMID: 25701368 DOI: 10.1016/j.trsl.2015.01.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
49 Masclee GM, Coloma PM, Spaander MC, Kuipers EJ, Sturkenboom MC. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. BMJ Open 2015;5:e006640. [PMID: 25633286 DOI: 10.1136/bmjopen-2014-006640] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
50 Falk GW. Barrett's oesophagus: frequency and prediction of dysplasia and cancer. Best Pract Res Clin Gastroenterol 2015;29:125-38. [PMID: 25743461 DOI: 10.1016/j.bpg.2015.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
51 Alsalahi O, Dobrian AD. Proton Pump Inhibitors: The Culprit for Barrett's Esophagus? Front Oncol 2014;4:373. [PMID: 25621278 DOI: 10.3389/fonc.2014.00373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
52 Tytgat GN. Reflections on esophageal columnar metaplasia (Barrett)-ANNO 2015. J Dig Dis 2015;16:55-7. [PMID: 25529483 DOI: 10.1111/1751-2980.12224] [Reference Citation Analysis]
53 Frazzoni M, Bertani H, Conigliaro R, Frazzoni L, Losi L, Melotti G. Neoplastic progression in short-segment Barrett’s oesophagus is associated with impairment of chemical clearance, but not inadequate acid suppression by proton pump inhibitor therapy. Aliment Pharmacol Ther. 2014;40:835-842. [PMID: 25087846 DOI: 10.1111/apt.12895] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
54 Hvid-Jensen F, Funch-Jensen P, Drewes AM. Letter: proton pump inhibitors, GERD and oesophageal adenocarcinoma - authors' reply. Aliment Pharmacol Ther 2014;40:320. [PMID: 25040747 DOI: 10.1111/apt.12847] [Reference Citation Analysis]
55 Rosch PJ. Letter: proton pump inhibitors, GERD and oesophageal adenocarcinoma. Aliment Pharmacol Ther 2014;40:319. [PMID: 25040746 DOI: 10.1111/apt.12832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]